Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course RT + Furoquintinib + PD-1 in Rectal Cancer
NCT06014944Phase 2Not yet recruiting
- Sponsor
- Changhai Hospital
- Start
- Sep 2023
- Primary completion
- Dec 2028
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
01
Overview
Phase 2, open-label, single-arm trial of fruquintinib and serplulimab in rectal cancer, sponsored by Changhai Hospital. Primary endpoint: Clinical Complete Response Rate at 5 years. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
fruquintinibserplulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06014944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06014944.